The Invus Group

Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. CONV 01-α, a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter, was specifically designed to bind to the prostate-specific membrane antigen (PSMA). A key functional feature of CONV 01-α is that, once bound to PSMA, it becomes internalized, thereby delivering its powerful radioactive payload directly into the prostate cancer cells. CONV 01-α is covered by multiple issued U.S. and foreign patents. If FDA-approved, CONV 01-α would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment.

Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company utilizes insights from its scientific founders to identify "switch sites," which are druggable regions that play a crucial role in regulating transcription factors and addressing disease-related mutations. Flare's innovative drug discovery efforts have led to a promising pipeline of drug programs targeting well-validated transcription factors, with an initial emphasis on precision oncology. The company's platform also holds potential for applications in neurology, rare genetic disorders, immunology, and inflammation, aiming to transform treatment approaches for various diseases.

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for viral-associated diseases. Its lead product, Viralym-M, targets several viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline also includes candidates for treating respiratory syncytial virus, influenza, SARS-CoV-2, hepatitis B, and human herpesvirus-8. AlloVir's proprietary VST therapy platform aims to provide accessible treatment options for patients facing severe viral infections, addressing the pressing need for effective therapies in this area. Founded in 2013, AlloVir was previously known as ViraCyte, Inc. and rebranded in May 2019.

Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.

MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.

Onxeo is a clinical-stage biotechnology company based in Paris, France, focused on developing innovative oncology drugs that target tumor DNA repair mechanisms. The company offers Beleodaq, a treatment for relapsed or refractory peripheral T-cell lymphoma, and is advancing several other candidates, including Livatag, a nanoparticle formulation of doxorubicin currently in Phase III trials for primary liver cancer. Validive, a buccal tablet for preventing and treating severe oral mucositis in head and neck cancer patients, has completed Phase II trials. Additionally, Onxeo is developing AsiDNA, which is undergoing Phase 1 trials for metastatic melanoma, and OX401, which is in preclinical development for DNA damage response and immuno-oncology applications. The company has established partnerships with Spectrum Pharmaceuticals for Beleodaq, Monopar Therapeutics for Validive, and Gustave Roussy for the clinical trials of AsiDNA in relapsed ovarian cancer. Onxeo, previously known as BioAlliance Pharma, was founded in 1997 and has a commitment to advancing oncology treatments worldwide.

Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.

Operator of a biotechnology company intended to provide novel small molecule medicines targeting g-protein-coupled receptors. The company provides industrial-scale drug discovery using novel screening technologies and structure-based drug design, enabling medical researchers to easily find patients' treatments for a wide range of diseases.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.

Asher Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapy drugs for cancer treatment. Founded in 2019 and headquartered in South San Francisco, California, the company aims to create innovative therapeutic solutions to improve patient outcomes in oncology. Asher Bio leverages advanced technologies and research to enhance the effectiveness of immune-based therapies, positioning itself as a key player in the evolving field of cancer treatment.

Laronde is focused on developing innovative therapeutics using its proprietary Endless RNA™ (eRNA) platform, which allows for the modulation of human biology through uniquely engineered RNA. This technology enables the expression of diverse proteins within the body while being persistent, non-immunogenic, and suitable for repeat dosing. Additionally, it provides flexibility in formulation and delivery, making it a promising foundation for new medicines. Founded in 2017 by Flagship Labs, Laronde is rapidly scaling its operations to support the simultaneous development of various programs targeting multiple disease areas, aiming to create more predictable and impactful treatments in the healthcare sector.

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Ring Therapeutics, Inc. is a biotechnology company that specializes in developing gene therapies through its innovative viral vector platform, Anellovector. This platform leverages the human commensal virome to create redosable and targetable DNA therapies, addressing key limitations of existing gene and DNA treatments, such as restricted access to diverse tissues and challenges with tolerability and genomic integration. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics aims to expand the scope of gene therapy beyond traditional gene replacement, enabling a broader range of applications across various medical fields, including genetic disorders, ophthalmology, oncology, and metabolic diseases. By focusing on cellular and tissue specificity, the company aspires to unlock new therapeutic possibilities for previously inaccessible conditions.

Lyndra Therapeutics, Inc. specializes in the development of ultra-long-acting oral medications that provide sustained drug release over extended periods, ranging from a week to a month. By focusing on orally administered dosage forms that temporarily reside in the stomach, the company aims to transform the way medicines are taken, reducing the need for daily pills. Its portfolio includes therapies targeting a variety of health conditions, such as Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is committed to enhancing medication adherence and improving health outcomes while also aiming to lower healthcare costs through innovative delivery methods.

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with progressive multiple sclerosis (MS) and other severe autoimmune and inflammatory diseases.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of innovative treatments for serious and orphan diseases. The company focuses on soluble guanylate cyclase (sGC) pharmacology to harness the therapeutic potential of next-generation sGC stimulators. Its key product candidates include Olinciguat, which is undergoing Phase II studies for sickle cell disease, and Praliciguat, currently in Phase II trials for diabetic nephropathy and heart failure with preserved ejection fraction. Additionally, Cyclerion is developing IW-6463, an orally administered central nervous system-penetrant sGC stimulator in Phase I trials aimed at treating neurodegenerative diseases. The company is also exploring liver-targeted and lung-targeted sGC stimulators to expand its therapeutic offerings. Cyclerion Therapeutics was incorporated in 2018 and is dedicated to addressing unmet medical needs through its innovative pipeline.

Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company utilizes insights from its scientific founders to identify "switch sites," which are druggable regions that play a crucial role in regulating transcription factors and addressing disease-related mutations. Flare's innovative drug discovery efforts have led to a promising pipeline of drug programs targeting well-validated transcription factors, with an initial emphasis on precision oncology. The company's platform also holds potential for applications in neurology, rare genetic disorders, immunology, and inflammation, aiming to transform treatment approaches for various diseases.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, focused on developing innovative cell replacement therapies for diabetes. The company is working on several product candidates, including VC-01, designed for type 1 diabetes, and VC-02, which facilitates blood vessel interaction with implanted pancreatic precursor cells. Their VCTX210 product utilizes a proprietary human stem cell line that helps prevent immune system rejection, eliminating the need for immunosuppressants. ViaCyte's therapies differentiate stem cells into pancreatic beta-cell precursors that are implanted in an encapsulation device, enabling the production of insulin in response to blood glucose levels. The company's aim is to provide long-term solutions for both type 1 and type 2 diabetes patients, reducing their dependence on insulin and minimizing associated health complications. Founded in 1999 and formerly known as Novocell, Inc., ViaCyte also has operations in Athens, Georgia.

Repertoire Immune Medicines is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on leveraging the capabilities of T cells to develop innovative therapies for cancer, autoimmune diseases, and infectious diseases. Founded in 2016, the company is engaged in clinical trials that utilize autologous T cells primed against specific cancer antigens, enhancing their effectiveness with IL-15. By creating a repertoire of T cell receptor (TCR)-antigen codes, Repertoire aims to characterize TCR-antigen pairs and design targeted immune medicines. This approach seeks to unlock the human immune system’s potential, providing new avenues for prevention and treatment of serious diseases.

Omega Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing genomic medicines aimed at curing diseases. Founded in 2016, the company utilizes its proprietary epigenomic programming platform to create Omega Epigenomic Controllers. These innovative controllers are designed to selectively modulate the activity of the human genome, allowing for precise tuning of gene expression to achieve therapeutic effects. By targeting specific cell types, Omega Therapeutics aims to transform human medicine through the direct control of genomic functions, offering potential solutions for a variety of diseases.

Asher Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapy drugs for cancer treatment. Founded in 2019 and headquartered in South San Francisco, California, the company aims to create innovative therapeutic solutions to improve patient outcomes in oncology. Asher Bio leverages advanced technologies and research to enhance the effectiveness of immune-based therapies, positioning itself as a key player in the evolving field of cancer treatment.

Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing exosome-based therapeutics for the treatment of severe diseases. Founded in 2016, the company leverages its proprietary technology to harness and engineer extracellular vesicles, known as exosomes, for the targeted delivery of nucleic acids and proteins. This innovative approach aims to enhance drug delivery to challenging areas, such as the brain and central nervous system, where conventional therapies often fall short. Evox’s mission is to improve human health by creating novel therapeutics that address significant medical needs, particularly for conditions with limited treatment options. The company has built a comprehensive intellectual property portfolio and is backed by prominent life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based drug delivery.

Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases such as liver disease NASH and specific cancers, with a focus on targeting dysfunctional metabolic pathways. It was founded in 2007 and headquartered in San Mateo, California.

Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.

Lexeo Therapeutics is a clinical-stage biotechnology company specializing in genetic medicines. The company develops adeno-associated virus (AAV)-mediated therapies, primarily in collaboration with Weill Cornell Medicine’s Department of Genetic Medicine. Its pipeline includes treatments for both rare and non-rare monogenic diseases, as well as hereditary and acquired conditions. Lexeo Therapeutics aims to address high unmet medical needs across various patient populations, focusing on both preclinical and clinical gene therapy candidates. The company is committed to advancing its clinical programs towards commercialization while maintaining research partnerships to enhance its preclinical pipeline.

Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.

FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.

Yumanity Therapeutics is a biotechnology company dedicated to transforming drug discovery for neurodegenerative diseases linked to protein misfolding. Founded in December 2014 by protein folding expert Susan Lindquist and biotech leader Tony Coles, Yumanity aims to develop innovative, disease-modifying therapies to address critical unmet medical needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company leverages proprietary platforms to identify potential therapeutic targets and has made progress in advancing a new chemical lead series specifically for Parkinson’s disease, while also exploring additional compounds for Alzheimer's disease and ALS.

Locanabio, Inc. develops RNA-targeted gene therapies to treat a spectrum of underserved diseases. It offers therapies for neuromuscular, neurodegeneration, and ophthalmology diseases. Locanabio, Inc. was formerly known as Locana, Inc. and changed its name to Locanabio, Inc. in July 2020. The company was founded in 2016 and is based in San Diego, California.

Faze Medicines is a biotechnology company established in 2020 and based in Cambridge, Massachusetts. The company focuses on developing small molecule drugs targeting the underlying drivers of disease pathology, particularly for conditions such as amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). Faze Medicines leverages innovative research on biomolecular condensates to create potential therapeutic breakthroughs. Through advanced screening and proteomics techniques, the company aims to pioneer new treatments for various diseases, including frontotemporal dementia (FTD) and DM1, thereby addressing significant unmet medical needs.

Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.

Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression in organ transplant recipients. Its lead product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all long-term immunosuppression therapy within twelve months of their transplant. Additionally, the company's technology facilitates the safe administration of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, minimizing the risks associated with traditional methods. Founded in 1988 and based in Louisville, Kentucky, with an office in Wellesley, Massachusetts, Talaris Therapeutics has transitioned from its former name, Regenerex, Inc., in March 2019. The company is currently in the late stages of clinical development, also exploring applications for patients with severe autoimmune and immune-mediated disorders.

Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.

I-Mab HK is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the areas of cancer and autoimmune disorders. The company is engaged in developing a diverse pipeline of product candidates, including Felzartamab, a CD38 antibody in Phase III trials for multiple myeloma, and Eftansomatropin, a long-acting human growth hormone for pediatric growth hormone deficiency. Other notable candidates include Olamkicept, an IL-6 blocker for ulcerative colitis, and Enoblituzumab, a B7-H3 antibody for head and neck cancer. I-Mab HK also has preclinical compounds targeting various conditions, including cancers and autoimmune diseases. The company has established strategic collaborations, such as with AbbVie, to enhance its development efforts. Founded in 2014 and headquartered in Shanghai, I-Mab HK is dedicated to advancing therapies that improve patient outcomes across various therapeutic areas.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and based in San Mateo, California, the company concentrates on targeting dysregulated transcription factors and the associated transcriptional regulatory networks that contribute to cancer progression. Its lead candidate, entospletinib, is a selective inhibitor aimed at spleen tyrosine kinase for treating acute myeloid leukemia. Additionally, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9, intended for the treatment of MYC-amplified solid tumors. The company employs advanced techniques, including high-throughput small-molecule microarrays and targeted protein degradation, to discover potent compounds that can effectively modulate challenging cancer targets.

Taysha Gene Therapies is a company focused on developing adeno-associated virus (AAV) based gene therapies aimed at treating monogenic diseases of the central nervous system. Founded in 2019 and based in Dallas, Texas, the company is advancing several therapeutic candidates, including TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies collaborates with The University of Texas Southwestern Medical Center to enhance the development and commercialization of its innovative treatments, with a mission to eradicate severe and life-threatening CNS diseases through curative gene therapies. The company's expertise in drug development and its partnership with a leading gene therapy program enable it to effectively progress its pipeline of potential therapies.

Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.

Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

Imvax, Inc. is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, focused on developing innovative patient-specific vaccines and immunotherapy strategies for treating malignant gliomas and other cancers that lack effective treatments. The company's lead product, IGV-001, is an autologous tumor cell vaccine designed to stimulate a robust immune response against tumor cells by utilizing the patient's own immune system. Imvax employs advanced methodologies, including patient cell harvest, treatment, and implants, as well as techniques that promote immunogenic cell death and activate both the innate and adaptive immune responses. Founded in 2015 by a team of experienced professionals, Imvax aims to address significant unmet medical needs in oncology through its novel therapeutic approaches.

Autobahn Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, dedicated to developing small molecule therapies for central nervous system (CNS) disorders. The company focuses on leveraging its expertise in brain-targeting chemistry to create innovative treatments that harness the regenerative capabilities of the human body. Its primary product candidate, ABX-002, is a thyroid hormone receptor beta agonist aimed at treating multiple sclerosis and adrenomyeloneuropathy, a rare genetic disorder. Founded in 2017, Autobahn Therapeutics is committed to addressing significant unmet medical needs in areas such as neuropsychiatry, neurodegeneration, and neuroinflammation, utilizing validated clinical and biological targets to guide its research and development efforts.

SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018 and headquartered in San Diego, California, Erasca utilizes its oncology pattern recognition algorithm (OPRA), an artificial intelligence-driven drug discovery platform, to analyze large-scale data sets and uncover novel tumor biology that can inhibit key cancer pathways. The company is advancing multiple drug candidates, including Naporafenib, an innovative pan-RAF inhibitor aimed at treating NRAS mutant melanoma and other RAS/MAPK-driven tumors, as well as ERAS-007 and ERAS-601, which are oral inhibitors targeting ERK1/2 and SHP2, respectively. Through collaborations with academic and biopharmaceutical partners, Erasca aims to expand its pipeline and provide new therapeutic options for cancer patients.

ITeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for cancer treatment. Founded in 2011 and headquartered in Gosselies, Belgium, with operational ties to Cambridge, Massachusetts, the company leverages its expertise in tumor immunology to create small molecule immunomodulators. Its product pipeline includes EOS-850, an antagonist of the adenosine A2a receptor, currently in an open-label Phase 1/2a clinical trial for adult patients, and EOS-448, which targets the TIGIT receptor and is also in a Phase 1/2a clinical trial. ITeos aims to enhance the effectiveness of cancer therapies by targeting resistance mechanisms within the tumor microenvironment, thereby improving the clinical outcomes of existing treatment modalities and newer immunotherapies.

Triplet Therapeutics, Inc. develops therapeutics and treatments for triplet disorders. It develops treatment for repeat expansion disorders, including Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias. Triplet Therapeutics, Inc. was formerly known as rzna, Inc. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatment. Founded in 2014 and based in South San Francisco, California, the company is advancing several product candidates, including ORIC-101, a small molecule antagonist of the glucocorticoid receptor associated with resistance to various cancer therapies in solid tumors. Another key candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, which plays a significant role in resistance to chemotherapy and immunotherapy regimens. In addition to these, ORIC is working on multiple precision medicines aimed at addressing other cancer resistance mechanisms. The company's founders, Charles Sawyers and Scott Lowe, are recognized for their contributions to identifying novel cancer targets that have led to innovative treatment options.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and based in San Mateo, California, the company concentrates on targeting dysregulated transcription factors and the associated transcriptional regulatory networks that contribute to cancer progression. Its lead candidate, entospletinib, is a selective inhibitor aimed at spleen tyrosine kinase for treating acute myeloid leukemia. Additionally, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9, intended for the treatment of MYC-amplified solid tumors. The company employs advanced techniques, including high-throughput small-molecule microarrays and targeted protein degradation, to discover potent compounds that can effectively modulate challenging cancer targets.

BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has pioneered innovative therapies through advanced computational discovery and drug development platforms. BioNTech's oncology pipeline includes various neoantigen-targeted therapies, such as NEO-PV-01 for advanced non-small cell lung cancer and multiple FixVac product candidates for different cancers, including melanoma, prostate cancer, and HPV-positive head and neck cancers. The company also explores mRNA vaccine candidates for infectious diseases and maintains collaborations with prominent pharmaceutical firms. BioNTech Cell & Gene Therapies GmbH, a subsidiary, specializes in developing T cell immunotherapies for cancer treatment.

Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.

AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for viral-associated diseases. Its lead product, Viralym-M, targets several viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline also includes candidates for treating respiratory syncytial virus, influenza, SARS-CoV-2, hepatitis B, and human herpesvirus-8. AlloVir's proprietary VST therapy platform aims to provide accessible treatment options for patients facing severe viral infections, addressing the pressing need for effective therapies in this area. Founded in 2013, AlloVir was previously known as ViraCyte, Inc. and rebranded in May 2019.

Foghorn Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, the company aims to understand and manipulate gene expression to develop innovative therapies for various diseases, particularly cancer. Foghorn is advancing several drug candidates, including FHD-286, an enzymatic inhibitor targeting BRG1 and BRM for acute myeloid leukemia and uveal melanoma, and FHD-609, a protein degrader aimed at treating synovial sarcoma. Additionally, the company has ongoing preclinical and discovery programs targeting non-small-cell lung cancer and other cancers associated with ARID1B mutations. Foghorn has established a collaboration with Merck Sharp & Dohme Corp. to create novel oncology therapeutics. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics is pioneering a new class of drug targets that could transform treatment approaches for patients with serious diseases.

Oyster Point Pharma, Inc. is a clinical-stage biopharmaceutical company based in Princeton, New Jersey, that specializes in the discovery, development, and commercialization of innovative therapies for ocular surface diseases. Founded in 2015, the company is primarily focused on its lead product candidate, OC-01, a nicotinic acetylcholine receptor agonist currently undergoing Phase III clinical trials for the treatment of dry eye disease. This condition, which affects over 30 million Americans, is characterized by a chronic lack of sufficient tears, leading to discomfort and potential vision problems. OC-01 is developed as a nasal spray and aims to restore tear film homeostasis by activating the trigeminal parasympathetic pathway, thereby stimulating natural tear production. Additionally, the company is exploring the use of OC-01 for neurotrophic keratitis, further expanding its therapeutic potential in ocular health.

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.

Lyndra Therapeutics, Inc. specializes in the development of ultra-long-acting oral medications that provide sustained drug release over extended periods, ranging from a week to a month. By focusing on orally administered dosage forms that temporarily reside in the stomach, the company aims to transform the way medicines are taken, reducing the need for daily pills. Its portfolio includes therapies targeting a variety of health conditions, such as Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is committed to enhancing medication adherence and improving health outcomes while also aiming to lower healthcare costs through innovative delivery methods.

KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.

SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.

Kaleido Biosciences is a clinical-stage healthcare company based in Lexington, Massachusetts, dedicated to developing microbiome metabolic therapies (MMTs) aimed at treating various diseases and improving human health. Founded in 2015, the company is advancing a diverse pipeline of MMT candidates targeting conditions such as urea cycle disorders, hepatic encephalopathy, multi-drug resistant infections, cardiometabolic and liver diseases, and immune oncology. Kaleido employs a unique, chemistry-driven approach to harness the microbiome's potential, focusing on modulating its metabolic output and profile by influencing the existing microbial functions. The company has established collaborations with notable institutions, including Gustave Roussy Cancer Center and Washington University School of Medicine, to further explore the applications of MMTs in immuno-oncology and other health conditions.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.

PACT Pharma, Inc. is engaged in developing personalized cell-based therapies aimed at treating cancer, specifically through neoantigen-specific adoptive TCR T-cell therapies for solid tumors. The company utilizes advanced bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying neoantigen peptides that provoke targeted T cell responses against cancer cells. By recognizing neo-epitopes, which are unique mutations in each patient's cancer, PACT Pharma creates autologous T cells engineered to specifically target and eliminate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is focused on innovative approaches to enhance cancer treatment through tailored immunotherapies.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.

BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, Germany, the company has pioneered innovative therapies through advanced computational discovery and drug development platforms. BioNTech's oncology pipeline includes various neoantigen-targeted therapies, such as NEO-PV-01 for advanced non-small cell lung cancer and multiple FixVac product candidates for different cancers, including melanoma, prostate cancer, and HPV-positive head and neck cancers. The company also explores mRNA vaccine candidates for infectious diseases and maintains collaborations with prominent pharmaceutical firms. BioNTech Cell & Gene Therapies GmbH, a subsidiary, specializes in developing T cell immunotherapies for cancer treatment.

Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.

Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.

Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.

Rebound Therapeutics Corp. focuses on developing single-use, disposable medical devices designed for access, imaging, and illumination in minimally invasive surgical procedures. Established in 2015 and based in Irvine, California, the company has made significant strides in product development over a short period, creating a unique range of devices aimed at enhancing procedural and clinical outcomes. Rebound has also formed a Scientific Advisory Board comprised of leading physicians in minimally invasive surgery and has secured 14 patents to protect its intellectual property. The company has completed pre-clinical studies that support its transition to initial human use, which is scheduled to commence soon. As of September 2019, Rebound Therapeutics operates as a subsidiary of Integra LifeSciences Holdings Corporation.

PatientsLikeMe, Inc. operates a healthcare data-sharing platform that allows patients to share their symptoms, treatments, and health experiences with a broad audience, including caregivers, researchers, and pharmaceutical companies. This platform aims to enhance the understanding of various health conditions, such as cancer, mental health issues, and chronic diseases, ultimately contributing to the development of new treatments. With over 600,000 members, PatientsLikeMe serves as a trusted source for real-world disease information and has published more than 100 research studies, demonstrating its commitment to integrating patient voices into research and public policy. The company collaborates with major pharmaceutical firms and government organizations to advance health management and outcomes. Founded in 2004 and based in Cambridge, Massachusetts, PatientsLikeMe is a subsidiary of United Healthcare Services, Inc.

Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Lexicon Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing pharmaceutical products aimed at treating various human diseases, including those related to immunology, metabolism, cardiology, and ophthalmology. The company's pipeline features several drug candidates, such as LX1031, which has completed Phase II trials for irritable bowel syndrome; LX4211, also in Phase II trials for type 2 diabetes; LX2931, currently undergoing Phase II trials for rheumatoid arthritis; and LX1032, which has completed Phase II trials for carcinoid syndrome symptoms. Additionally, the company is developing LX7101 for glaucoma in preclinical stages and is working on LX9211 for neuropathic pain, along with sotagliflozin for heart failure and type 1 diabetes. Lexicon has formed strategic alliances and collaborations with various pharmaceutical companies and research organizations to enhance its drug discovery and development capabilities.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

PatientsLikeMe, Inc. operates a healthcare data-sharing platform that allows patients to share their symptoms, treatments, and health experiences with a broad audience, including caregivers, researchers, and pharmaceutical companies. This platform aims to enhance the understanding of various health conditions, such as cancer, mental health issues, and chronic diseases, ultimately contributing to the development of new treatments. With over 600,000 members, PatientsLikeMe serves as a trusted source for real-world disease information and has published more than 100 research studies, demonstrating its commitment to integrating patient voices into research and public policy. The company collaborates with major pharmaceutical firms and government organizations to advance health management and outcomes. Founded in 2004 and based in Cambridge, Massachusetts, PatientsLikeMe is a subsidiary of United Healthcare Services, Inc.

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, CA, specializes in developing products that combine state-of-the-art medical devices with advanced pharmaceuticals. The company's next-generation drug-eluting stent systems are designed to optimize localized drug delivery to provide a safe and effective treatment for cardiovascular patients.

Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.